ReviewFrontiers in microbiology2022
Fungal Infection in Co-infected Patients With COVID-19: An Overview of Case Reports/Case Series and Systematic Review.
Review in Frontiers in microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed.
- Pulmonary Drug Delivery for Infectious Diseases: Cutting-Edge Formulations and Manufacturing Technologies.Pharmaceutics · 2026Review
- Burden of adverse transplant outcomes in kidney transplant recipients with COVID-19 and invasive fungal infections: a retrospective cohort study.BMC infectious diseases · 2026Article
- Understanding the biology of mucormycosis using contemporary omics tools: a review.Biotechnologia · 2026Review
- Therapeutic Potential of White Kidney Beans (Foods (Basel, Switzerland) · 2025Review
- COVID-19-Associated Mucormycosis: Identifying Mortality Predictors in a Retrospective Cohort Study.Open forum infectious diseases · 2025Article
- Fruiting Bodies of Aspergillus in a Cavitary Lung Mass: A Rare Finding on Fine Needle Aspiration.Diagnostic cytopathology · 2025Article
- Clinical characteristics of patients with COVID-19-associated mucormycosis (CAM) hospitalized at Shafa Hospital, Kerman: 2022.BMC infectious diseases · 2025Article
- Pulmonary Aspergillosis in Immunocompromised Critically Ill Patients: Prevalence, Risk Factors, Clinical Features and Diagnosis-A Narrative Review.Journal of fungi (Basel, Switzerland) · 2025Review
- Agglutination of yeast-binding antibodies from human blood plasma products.BMC microbiology · 2025Article
- Detection of Siderophores as a Superior Noninvasive Diagnostic Tool in Unraveling Mixed Fungal Infections.ACS omega · 2025Article
- The diagnostic value of combinedFrontiers in medicine · 2025Article
- MICROBIAL PATTERNS AND DRUG SENSITIVITY TEST OF BACTERIAL AND FUNGAL INFECTION IN COVID-19 PATIENTS AT THE NATIONAL REFERRAL HOSPITAL IN NORTH SUMATRA, INDONESIA.African journal of infectious diseases · 2025Article
- Comparison of clinical characteristics and outcomes in candidaemia patients with and without COVID-19: a multicentre retrospective study.BMC infectious diseases · 2024Article
- Identification of fungal pathogens among COVID-19 and non COVID-19 cases in Bhaktapur hospital, Nepal.BMC research notes · 2024Article
- Invasive Fungal Infections in Immunocompromised Conditions: Emphasis on COVID-19.Current microbiology · 2024Review
- The activating receptor NKG2D is an anti-fungal pattern recognition receptor.Nature communications · 2024Article
- Fungal coinfection/superinfection in COVID-19 patients in a tertiary hospital in MexicoBiomedica : revista del Instituto Nacional de Salud · 2024Article
- Influence of Mycobiota in the Nasopharyngeal Tract of COVID-19 Patients.Microorganisms · 2024Article
- Article
- Outcomes of Patients with COVID-19 and Fungal Coinfections: A Systematic Review and Meta-Analysis Study.Iranian journal of pathology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fungal co-infections are frequent in patients with coronavirus disease 2019 (COVID-19) and can affect patient outcomes and hamper therapeutic efforts. Nonetheless, few studies have investigated fungal co-infections in this population. This study was performed to assess the rate of fungal co-infection in patients with COVID-19 as a systematic review. EMBASE, MEDLINE, and Web of Science were searched considering broad-based search criteria associated with COVID-19 and fungal co-infection. We included case reports and case series studies, published in the English language from January 1, 2020 to November 30, 2021, that reported clinical features, diagnosis, and outcomes of fungal co-infection in patients with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Totally, 54 case reports and 17 case series were identified, and 181 patients (132 men, 47 women, and 2 not mentioned) co-infected with COVID-19 and fungal infection enrolled. The frequency of fungal co-infection among patients with COVID-19 was 49.7, 23.2, 19.8, 6.6, and 0.5% in Asia, America, Europe, Africa, and Australia, respectively. Diabetes (59.6%) and hypertension (35.9%) were found as the most considered comorbidities in COVID-19 patients with fungal infections. These patients mainly suffered from fever (40.8%), cough (30.3%), and dyspnea (23.7%). The most frequent findings in the laboratory results of patients and increase in C-reactive protein (CRP) (33.1%) and ferritin (18.2%), and lymphopenia (16%) were reported. The most common etiological agents of fungal infections were
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.